Physiologically-based pharmacokinetic simulation modelling.
about
The use of ROC analysis for the qualitative prediction of human oral bioavailability from animal data.Integrating in vitro ADMET data through generic physiologically based pharmacokinetic models.Practical experience of using human microdosing with AMS analysis to obtain early human drug metabolism and PK data.Use of probabilistic modeling within a physiologically based pharmacokinetic model to predict sulfamethazine residue withdrawal times in edible tissues in swine.Physiologically based pharmacokinetic modeling: methodology, applications, and limitations with a focus on its role in pediatric drug development.BioDMET: a physiologically based pharmacokinetic simulation tool for assessing proposed solutions to complex biological problems.Human tissue in the evaluation of safety and efficacy of new medicines: a viable alternative to animal models?The use of biopharmaceutic classification of drugs in drug discovery and development: current status and future extension.Drug compounding for veterinary patients.Evaluation and suggested improvements of the Biopharmaceutics Classification System (BCS).Prediction of human pharmacokinetics--gastrointestinal absorption.In vitro models for processes involved in intestinal absorption.Assessment of juvenile pigs to serve as human pediatric surrogates for preclinical formulation pharmacokinetic testing.Physiologically based approaches towards the prediction of pharmacokinetics: in vitro-in vivo extrapolation.A simplified PBPK modeling approach for prediction of pharmacokinetics of four primarily renally excreted and CYP3A metabolized compounds during pregnancyGut Wall Metabolism. Application of Pre-Clinical Models for the Prediction of Human Drug Absorption and First-Pass Elimination.Early human ADME using microdoses and microtracers: bioanalytical considerations.Pros and cons of methods used for the prediction of oral drug absorption.Overview of challenges and opportunities in drug delivery and pharmaceutics.Lipid-associated oral delivery: Mechanisms and analysis of oral absorption enhancement.Physiologically-based pharmacokinetic models: approaches for enabling personalized medicine.Physiologically based pharmacokinetic model for quinocetone in pigs and extrapolation to mequindox.WebPK, a web-based tool for custom pharmacokinetic simulation.Animal versus human oral drug bioavailability: do they correlate?Sensitivity and proportionality assessment of metabolites from microdose to high dose in rats using LC-MS/MS.QSARs for PBPK modelling of environmental contaminants.Rat poorly predicts the combined non-absorbed and presystemically metabolized fractions in the human.In Silico ADME/Tox PredictionsApplication of a Novel 'Make and Test in Parallel' Strategy to Investigate the Effect of Formulation on the Pharmacokinetics of GDC-0810 in Healthy Subjects
P2860
Q30670381-925CAF43-174E-4153-B4A2-4B56CA1C8F35Q31049476-05FD4047-40A3-4E67-B3D6-A61750B41C7BQ33748891-E6E9860C-6147-42A6-8EF4-184B0FEDD3DBQ34721486-5CB7E8C5-5D27-43FA-93BE-30073C665B89Q35054518-D74C818B-ACF5-4154-881E-69A9381DBE5FQ35673015-8C47C552-C867-4C23-A7BD-A94FB015A7C0Q35687753-5B2EE7D9-1B97-446E-87BC-58B82B98D1D6Q36088451-7C7F4411-E125-48E0-A0E2-2E95025B2858Q36341582-EF317F7B-ACF2-4BCF-B452-31425DE10CB0Q36885229-6AFD88A2-097D-4E3D-9757-7395C090C486Q36885247-0DE53B60-66D3-40A0-AC88-98C0B8632BD7Q36909324-E8C32111-4DF2-4461-B719-8D90AD7104B4Q36951897-C81DB44B-0132-4746-94B5-684ECD4E073CQ37008900-A076CCE4-521F-470F-A687-2BE7A4BCFCEAQ37207844-5520398F-F43D-4511-8C39-69EA01FB8893Q37600381-D8443939-D833-422B-9CDE-C28346DCD66BQ37810234-E970165F-C778-41A6-9BFD-39CC6E59F7D0Q38177366-DB105522-C28A-4D0F-A00D-1493F99B8E77Q38573488-28A95C29-898D-4F6B-A851-8E47FC9CA378Q38926514-4AD7784D-E0A1-41F4-B175-C67D19B30347Q38959281-9B4B597F-7C81-4DF8-82C9-C6B4E490DF88Q39077905-3321F75B-9C50-48E2-9935-F70CF584A7ABQ40965484-406A7DEF-9056-416E-B2E2-05DD710E579CQ42744069-2052EDD1-8E19-43D0-95A2-E0A2B0FF942EQ42807076-768C1460-C77C-4DA6-8736-E1DCE782DA12Q45995747-57D8DDB7-B93B-40AC-82F2-3FE7DE9EF0C7Q46977325-AAAA6E4C-C120-4C9F-A70B-677049DC4EC2Q56984194-F716FF32-D23F-4426-8594-680EB5E66991Q57465370-6F1BDDE4-D1D6-43A6-8456-93423A2D49EB
P2860
Physiologically-based pharmacokinetic simulation modelling.
description
2002 nî lūn-bûn
@nan
2002 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի մարտին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Physiologically-based pharmacokinetic simulation modelling.
@ast
Physiologically-based pharmacokinetic simulation modelling.
@en
Physiologically-based pharmacokinetic simulation modelling.
@nl
type
label
Physiologically-based pharmacokinetic simulation modelling.
@ast
Physiologically-based pharmacokinetic simulation modelling.
@en
Physiologically-based pharmacokinetic simulation modelling.
@nl
prefLabel
Physiologically-based pharmacokinetic simulation modelling.
@ast
Physiologically-based pharmacokinetic simulation modelling.
@en
Physiologically-based pharmacokinetic simulation modelling.
@nl
P1476
Physiologically-based pharmacokinetic simulation modelling
@en
P2093
George M Grass
P304
P356
10.1016/S0169-409X(02)00013-3
P407
P577
2002-03-01T00:00:00Z